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KEY POINTS
 Radiation therapy is one of the most effective treatment modalities in cutaneous T-cell lymphomas.
 Local radiation therapy is potentially curative in unilesional mycosis fungoides.
 Local radiation therapy can effectively palliate symptomatic lesions in patients with cutaneous
T-cell lymphoma.
 Total skin electron beam therapy should be used in patients with diffuse mycosis fungoides
unresponsive to other modalities or when thick plaques or tumors are present.INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) are
comprised of several histologic subtypes of non-
Hodgkin lymphoma characterized by localization
of malignant lymphocytes to the skin. Mycosis fun-
goides (MF) is themost common type of CTCL, ac-
counting for 54% of CTCL diagnoses from 2001 to
2005 in one Surveillance, Epidemiology, and End
Results registry review.1 Other subtypes of CTCL
include cutaneous CD301 T-cell lymphoprolifera-
tive disorders and primary cutaneous peripheral
T-cell lymphomas.
Radiation therapy (RT) is one of the most effec-
tive treatment modalities for CTCL. Lymphocytes
are among the most radiosensitive of all cells.
Low doses of radiation yield impressive local re-
sponses with minimal side effects. For patients
with MF, RT has several different clinical applica-
tions. For the rare patient with unilesional disease,
RT alone is potentially curative. For patients withNo disclosures.
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under the CC BY-NC-ND license (http://creativecommons.more advanced cutaneous disease, RT to local
lesions or to the entire skin can effectively palliate
symptomatic disease and provide local disease
control. Finally, symptomatic nodal or visceral dis-
ease can also be palliated with RT if necessary.
This article reviews basic information regarding
the administration of RT and reviews the published
literature supporting the use of such for MF and
primary cutaneous anaplastic large cell lymphoma
(cALCL). Cutaneous peripheral T-cell lymphomas
are rare and are not discussed further.
MYCOSIS FUNGOIDES
Local Radiation Therapy
In rare circumstances, MF presents as a solitary
lesion, or small number of clustered lesions, that
areamenable toadefinitivecourseof therapywhere
the goal of treatment is long-term disease control.
More commonly, patients with MF have more
diffuse presentations where symptom palliationical Center, DUMC BOX 3085, Durham, NC 27710, USA
ublished by Elsevier Inc. This is an open access article
org/licenses/by-nc-nd/4.0/).
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Tandberg et al704and local disease control are the fundamental goal
of treatment. In circumstances where other modal-
ities are not effective or a rapid response is desired,
local RT can be efficacious. These circumstances
include cosmetically disfiguring lesions on the
face; tumors and thick plaques where radiation
can effectively treat to the necessary depth; and le-
sions that are painful, pruritic, or weeping.
Clinical applications of local radiation therapy
Minimal stage IA disease Patients with patches or
plaquescovering less than10%of thebody surface
area without significant blood, nodal, or visceral
involvement have clinical stage IA MF. These pa-
tients have a favorable prognosis with survival
similar to age-matched control subjects without
MF.2 In a retrospective cohort analysis including
121 patients with clinical stage IA disease, the me-
dian survival had not been reached after more than
32 years of follow-up. Three (2%) of 122 patients
had died of MF during the study period.
The subgroup of patients with “minimal” stage
IA MF (ie, unilesional or up to three close lesions)
have an especially favorable prognosis. Patients
with this disease may experience long-term remis-
sion or ostensibly even “cure” with local RT alone.
Several small studies have reported outcomes of
local RT in minimal stage IA disease. Results of
these studies are summarized in Table 1. Wilson
and colleagues3 evaluated 21 patients with mini-
mal disease treated with local RT. Thirteen pa-
tients had unilesional MF. The complete
response (CR) rate to localized RT was 97%.
Disease-free survival (DFS) for the entire group at
5 and 10 years was 75% and 64%, respectively.
Improved DFS at 10 years was reported in patients
with unilesional disease (85%) and those receiving
doses of at least 20 Gy (91%).
Micaily and colleagues4 reported on the out-
comes of 18 patients with unilesional stage IA
MF. This represented only 5% (18 of 325) of
patients with MF treated at the study institution.
Most patients received 30.6 Gy of local RT.
The CR rate was 100%. Relapse-free survival
(RFS) and overall survival at 10 years was 86%Table 1
Outcomes of local radiation therapy in minimal stag
Study (Ref)
Extent of
Disease
No. of
Patients
No. of
Sites
R
(
Wilson et al,3 1998 1–3 lesions 21 32 2
Micaily et al,4 1998 1 lesions 18 18 3
Piccinno et al,5 2009 1–4 lesions 15 22 2
Abbreviations: CR, complete response; DFS, disease-free survivand 100%, respectively. Two relapses occurred,
both confined to the skin at distant sites and sub-
sequently treated with topical nitrogen mustard.
Finally, Piccinno and colleagues5 evaluated 15
patients with minimal stage MF treated with a me-
dian dose of 22 Gy. Complete remission of treated
lesions was observed in 95% with the other 5%
achieving a partial remission. At 5 and 10 years
the overall relapse-free rate was 51%.
In summary, less than 5% of patients present
with minimal stage IA MF. This unique subgroup
may be managed effectively with local RT alone.
Available studies report excellent responses to
local RT with 95% to 100% of lesions experiencing
a CR. Many patients have a prolonged disease-
free interval with the best outcomes seeming to
be with RT doses of 20 to 30 Gy.
Palliation of individual lesions Local RT is an
effective palliative therapy for patients with all
stages of MF with symptomatic cutaneous lesions.
Local RT is often used to treatMF lesions refractory
to other skin-directed or systemic therapies.
Several retrospective studies have demonstrated
very high rates of CR (>95%) of individual MF le-
sions with fractionated courses of RT.3–6 A dose–
response relationship has emerged with higher
doses being associated with higher rates of CR
and local control. Cotter and colleagues6 evaluated
the impact of radiation dose on local control in
111 MF lesions (53% plaques, 47% tumors). They
demonstrated a CR to treatment in all lesions
receiving greater than 20 Gy. Local recurrence
was inversely associated with dose. The rate of
local in-field recurrence was 42% with doses less
than or equal to 10 Gy, 32% for doses 10 to
20 Gy, 21% for doses 20 to 30 Gy, and 0% when
the dose was greater than 30 Gy. There was no dif-
ference in response rates between plaques and tu-
mors. It was suggested that tumor doses
equivalent to 30 Gy at 2 Gy per fraction were
required for adequate control of MF lesions.
Palliation of individual skin lesions with very
short courses of RT has also been reported. Short
courses of radiation are more convenient fore IA mycosis fungoides
T Dose
Median) CR Rate
Relapse in
RT Field DFS 5 y DFS 10 y
0 Gy 97% 3/31 75% 64%
0.6 Gy 100% 0/18 NR 86%
2 Gy 95% 4/22 51% 51%
al.
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compared with multiple fractions. Thomas and
colleagues7 reported their experience treating
270 CTCL lesions (primarily MF) with a single frac-
tion of local RT. Of the 58 patients included in the
study, 21 (36%) had patch/plaque disease, 34
(59%) had tumor-stage disease, and 3 (5%) had
erythroderma only. Most patients (97%) were
treated with a single dose of greater than or equal
to 7 Gy. A CR was observed in 94% of lesions and
the rate of relapse in the radiation field was 1%
with a median follow-up of 41.8 months. Large-
cell transformation and tumor morphology were
associated with a lower CR rate. Neelis and col-
leagues8 reported a CR rate of 92% when patients
with MF were treated to a total dose of 8 Gy in two
fractions. Local relapse occurred in 8% of treated
sites. Of note, only 30% of lesions treated with
4 Gy in two fractions achieved a CR. Patients
who either did not have a CR or failed locally
were retreated with 20 Gy in eight fractions without
complication. No significant acute or long-term
toxicities were reported in either study.
In summary, local RT is very effective in the palli-
ation of MF skin lesions. Short courses of one to
two fractions (7–8 Gy) have yielded favorable re-
sults and can be used for patients requiring rapid
palliation or who would have a difficult time com-
ing in for a more conventional regimen. Generally,
smaller lesions are optimally suited for a single
fraction of treatment, whereas larger lesions are
often better managed with a more protracted frac-
tionated approach.
Palliation of nodal and visceral disease Most pa-
tients with MF never develop symptomatic nodal
or visceral disease. However, just as with other
malignancies, local RT can be used in this setting
for symptom palliation. Patients with advanced-
stage MF may experience pain, swelling, or other
local symptoms secondary to bulky lymphade-
nopathy. Visceral metastatic disease can impact
the function of an involved organ. RT in these cir-
cumstances is typically performed with computed
tomography (CT)–based three-dimensional plan-
ning with megavoltage photon RT. Typical doses
used in our institution range from 20 to 30 Gy using
2- to 3-Gy fractions.Side effects
Acute and long-term side effects of local RT
directed at skin lesions are minimal. Patients may
develop erythema and occasionally dry or moist
desquamation within the treatment field. Ulcerated
lesions sometimes appear worse shortly after
starting RT. The skin generally heals rapidly after
a course of radiation. Nothing more than topicalsymptom management is typically necessary dur-
ing treatment. In the long-term patients may have
pigmentation changes and alopecia in the treated
areas. There is a theoretic risk of secondary cuta-
neous malignancies, although reports of this in the
literature are rare.9
Technique and administration
Local RT is typically delivered by means of a linear
accelerator (Fig. 1). Most linear accelerators can
produce high-energy photon (x-rays) and electron
beams. Both photons and electrons can be used
depending on the clinical circumstances. Elec-
trons have unique properties that make them
particularly suited to treating cutaneous lesions.
Electron beam therapy delivers dose close to the
skin surface after which the dose falls off
extremely rapidly, limiting radiation exposure to
deeper tissues. Increasing electron energies can
be chosen to treat deeper lesions. The association
between the depth dose and electron energy is
plotted in Fig. 2.
Most electron beam treatments for superficial
skin lesions are planned clinically rather than with
imaging modalities, such as CT or MRI (Fig. 3).
The radiation oncologist delineates a margin of
1- to 2-cm around visible and/or palpable disease.
A lead cutout is then created conforming to the
shape of the target. The lead cutout is inserted
into the treatment machine thus focusing the radi-
ation beam to the desired shape. As electrons
begin depositing their dose on contact with the
skin, there can be some degree of “skin sparing”
with electron beam therapy (see Fig. 2). To
address this phenomenon, material referred to as
bolus is placed over skin lesions before treatment.
Bolus is a tissue-equivalent material that starts the
process of dose deposition allowing the maximum
dose to be at the skin surface. The radiation dose
is often fractionated, or divided into multiple
smaller doses. Patients are treated daily excluding
weekends until their course is completed. Each
treatment, including time for set-up, lasts approx-
imately 15 minutes.
Photon radiation is often used to treat nodal and
visceral disease because the dose penetrates
deeper than electrons. Photon beams are occa-
sionally required to treat thick cutaneous tumors.
Patients receiving photon radiation must first un-
dergo a radiation planning session termed a simu-
lation. The patient is immobilized and a planning
CT is performed. The radiation oncologist then
uses the planning CT scan and advanced treat-
ment planning software to plan the radiation treat-
ment. The gross disease is identified and
contoured on the planning scan. Margins are
created around this volume to account for
Fig. 1. Medical linear accelerator used to generate and deliver external beam radiation therapy.
Fig. 2. Plot of percentage of radiation dose (%) versus depth (mm) for various electron beam energies from 6 to
22 MeV.
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Fig. 3. Method of local electron beam radiation therapy to cutaneous lymphoma lesions. A margin is drawn
around visible or palpable disease (A). A lead cutout is created conforming to the target volume (B). The patient
is positioned on the treatment table and the electron beam therapy is delivered by a medical linear accelerator
(C). Note the bolus material placed over the cutaneous lesion that ensures the maximum dose is delivered to the
skin surface (arrow).
707Radiation Therapy for Cutaneous T-Cell Lymphomassubclinical disease and variations in daily set-up.
The optimal number and configuration of radiation
beams to treat the target volume and limit dose to
normal sensitive tissues is then determined. Pa-
tients are treated daily in the same position as their
planning scan. Proper positioning is ensured by
alignment to skin markings placed at the time of
planning and imaging taken immediately before
treatment.
Total Skin Electron Beam Therapy
Many patients with MF present with diffuse cuta-
neous disease or develop such during the course
of their illness. Multiple systemic and skin-
directed therapies have been used for diffuse dis-
ease, including total skin electron beam therapy
(TSEBT). TSEBT is used when RT is recommended
and the distribution of disease is such that the
entire skin surface requires treatment.
TSEBT is a technically challenging procedure
where radiation is delivered to the entire skin
surface. It requires special commissioning (ie,
configuring) of a linear accelerator and signifi-
cant support from medical physics. Thus, thistreatment is generally only available at larger
centers that treat many patients a year. As with
local RT, TSEBT is very effective with nearly all
patients experiencing significant clinical im-
provement. Continued research is exploring
dose reduction of TSEBT and concurrent and
adjuvant therapies.Clinical indications
Early stage (T1) TSEBT has shown favorable re-
sults in early stage MF. Ysebaert and colleagues10
demonstrated an 88% CR rate in patients T1 MF
treated to a mean dose of 30 Gy. Five-year RFS
was 75%. Hoppe and colleagues11 showed com-
plete regression of all skin lesions in 86% of pa-
tients with limited plaque disease. Finally, Jones
and colleagues12 reported a CR rate of 95% in pa-
tients with stage IA MF treated with 31 to 36 Gy.
Progression-free survival (PFS) at 15 years was
35%. However, because there are numerous other
effective therapies with less acute side effects,
TSEBT is generally not recommended as first-line
treatment of patients with limited or localized
skin involvement (T1).13,14
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TSEBT is the palliation of patients with severe skin
symptomsor generalized thick plaque or tumor dis-
ease (T2-T3).14 These patients have often had a
poor response to previous therapies. Clinical re-
sponses are correlated to tumor stage at presenta-
tion (T2 vs T3)15 and the extent of skin
involvement.16 For patients with T2 disease the
rate of CR has been reported to be 75% to 85%
with 50% RFS at 5 years but only 10% at
10 years.10,15,17 With T3 disease, CR rates of 43%
to 78% have been reported with nearly all patients
eventually experiencing recurrent disease.15,16
The largest reported series on TSEBT in T2 and
T3 MF was published by Navi and colleagues15
from Stanford. They included 103 patients with
T2 MF and 77 patients with T3 MF, all treated
with doses greater than 30 Gy. All patients had
clinically significant improvement in their disease
(>50% improvement in skin involvement). The CR
rate was 63%, including 75% in patients with T2
MF and 43% in patients with T3 MF. The median
duration of response (in complete responders)
was 29 months in patients with T2 disease and
9 months for patients with T3 disease. The 5-
and 10-year overall survival rates for the cohort
were 59% and 40%, respectively.
Ysebaert and colleagues10 reported an 85% CR
to TSEBT in patients with T2 MF. Five-year RFS
was 28%. Quiros and colleagues16 reported the
outcomes of 46 patients with T3 MF treated with
TSEBT. A total of 36 of 46 patients (78%) had a
cutaneous CR. DFS was 12% at 36 months.
Erythrodermic (T4) disease There is limited experi-
ence of TSEBT for patients with erythrodermic (T4)
MF. Jones and colleagues18 reported the out-
comes of 45 patients with T4 disease treated
with TSEBT without neoadjuvant, concurrent, or
adjuvant therapies. The rate of complete cuta-
neous remission was 60% with 26% remaining
disease-free at 5 years. Improved outcomes
were seen in patients with stage III disease without
blood involvement and in patients treated with a
more intensive TSEBT regimen (32–40 Gy).
Another retrospective study demonstrated im-
proved PFS and cancer-specific survival with the
addition of extracorporeal photophoresis (ECPP)
to TSEBT in T4 MF.19Special circumstances with total skin electron
beam therapy
Retreatment A second course of TSEBT is
feasible and safe in most circumstances. Ideal
candidates for such include those who achieved
a good response to the first course of TSEBT
with reasonable response duration, failure ofsubsequent treatments, and generalized symp-
tomatic skin involvement.20
Several small studies support the tolerability and
efficacy of multiple courses of TSEBT in MF. In
general, the dose of a second (and sometimes
third) course of TSEBT should be reduced. Becker
and colleagues21 described the experience of 15
patients treated with a second course of TSEBT
to a mean of 23.4 Gy (mean of first course was
32.6 Gy). A CR to the first course was achieved
in 11 of 15. Six patients had a CR and nine
achieved a partial response to the second course.
Long-term toxicities were mild and consisted of
generalized xerosis, scattered telangiectasias,
pigmentation changes, and partial alopecia.
Wilson and colleagues22 reported on 14 patients
with recurrent MF treated with multiple courses of
TSEBT (two to three courses). The median cumu-
lative dose for the entire cohort was 57 Gy. After
the first course, 13 of 14 patients had a CR. After
the second course, 12 of 14 had a CR, again
showing that a good response can be achieved
even when disease relapses after prior RT. The
median disease-free interval after the first course
of therapy for those with a CR was 20 months
and 11.5 months after the second course. Overall
the repeat treatments were well tolerated with no
severe toxicities.
Adjuvant therapies Patients with advanced MF
receiving TSEBT inevitably relapse. Several studies
have attempted to lengthen the disease-free inter-
val after TSEBT by using adjuvant therapies, such
as topical nitrogen mustard, oral psoralen plus ul-
traviolet light, oral etretinate, ECPP, interferon,
and cytotoxic chemotherapy. Unfortunately, most
of these studies are small, retrospective, and
from single institutions. Prospective, randomized
data are needed to confirm their results.
Chinn and colleagues23 initially demonstrated a
longer freedom from relapse in patients with T2
disease treated with adjuvant topical nitrogen
mustard compared with observation after TSEBT.
However, a larger more recent series from the
same institution showed no clinical advantage to
adjuvant topical nitrogen mustard.15 Quiro´s and
colleagues24 reported a significant benefit in DFS
but no significant overall survival advantage in
patients receiving adjuvant psoralen plus ultravio-
let A. Roberge and colleagues25 demonstrated
concurrent and adjuvant alpha interferon to be
tolerable but there was no significant difference
in PFS or overall survival. A more recent study
similarly showed no clinical benefit with the addi-
tion of interferon to TSEBT.26 Wilson and col-
leagues19,27 have reported on their experience
with concurrent/adjuvant ECPP in patients with
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borderline significant improvement in overall sur-
vival with ECPP.27 Another reported improved
DFS and cancer-specific survival in patients with
T4 disease.19 Finally, adjuvant systemic chemo-
therapy (cyclophosphamide/doxorubicin) has
been shown to have no benefit for RFS or overall
survival in one study27 but to improve RFS among
stage I/II patients in another.28 In short, the data
are mixed whether adjuvant therapies after TSEBT
are clinically beneficial.
Total skin electron beam therapy before stem cell
transplant Select patients with advanced-stage,
refractory MF are deemed appropriate candidates
for an autologous or allogeneic stem cell trans-
plant. Patients should, ideally, be in CR before initi-
ating the conditioning regimen for transplant.
TSEBT can be used to control cutaneous disease
and achieve remission in the skin. Total-body irra-
diation can also be used in the conditioning
regimen.
Duvic and colleagues29 reported their experi-
ence with 19 patients who received TSEBT
(36 Gy) immediately before allogeneic transplanta-
tion for refractory MF (median of four prior thera-
pies). Three patients had stage IIB disease (all
with large cell transformation), six had stage IVA
disease, and 10 had stage IVB disease. The rate
of CR was 58% after TSEBT and transplant. At
2 years, overall survival was 79% and PFS 53%.
The authors also suggested that TSEBT may
have helped to reduce the severity of posttrans-
plantation cutaneous graft-versus-host disease.Technique and administration
The European Organization for Research and
Treatment of Cancer (EORTC) has published
consensus guidelines regarding the use of TSEBT
in MF.17 The goal of TSEBT is to deliver a relatively
uniform dose of radiation to the entire skin while
limiting acute and long-term toxicities. Modern
TSEBT as delivered by linear accelerator was
largely developed at Stanford and today the “Stan-
ford technique” is commonly used.20,30 Many
modifications of this technique now exist.
The patient is positioned standing approxi-
mately 3 to 4 m from the linear accelerator. A 6-
to 9-MeV electron beam is used. A polycarbonate
screen is often placed between the linear acceler-
ator and the patient, which attenuates or scatters
the beam to increase the dose to the skin surface.
The patient is treated in six different standing
positions including anterior, posterior, right poste-
rior oblique, left posterior oblique, left anterior ob-
lique, and right anterior oblique (Fig. 4). All six
positions are treated over the course of 2treatment days, three positions on Day 1 and three
positions on Day 2. This cycle is repeated twice
per week. Treatment of each position is accom-
plished with a dual-field technique where the linear
accelerator is angled up to treat the superior field
and down to treat the inferior field. The use of
angled beams helps to fit the patient in the radia-
tion treatment field. The EORTC recommends
that the 80% isodose line extend to 4 mm below
the skin surface.17
Certain areas of the body are more susceptible
to side effects from RT and may require shielding
during portions of the treatment. Internal or
external eye shields are used to protect the eyes
during treatment (Fig. 5). Internal lead shields
placed underneath the eyelids are used when
there is disease on the face. External eye shields
can be used for portions of the treatment, espe-
cially in the absence of disease on the face. At
our institution we also commonly use mouth
shields covering the lips and oral mucosa to pre-
vent the development of mucositis. Blisters can
occasionally develop on the feet, which can cause
significant disability and delay patients from
completing the treatment as planned. At our insti-
tution, the hands and feet are shielded in the
TSEBT fields and treated separately with photon
fields.
Certain areas of the body may be underdosed or
even overdosed during TSEBT because of shad-
owing, body habitus, or peculiarities inherent in
treating with TSEBT. In a study byWeaver and col-
leagues,31 thermoluminescent monitors were
placed on several body locations to record the
dose received during TSEBT. Areas that routinely
receive a lower dose include the top of head, peri-
neum, upper inner thighs, and inframammary fold
region in women. These areas may be treated
with supplemental local electron beam either dur-
ing or after completion of the TSEBT. For patients
with tumors, a supplemental course of local RT
can be given at the start of TSEBT to rapidly
reduce the thickness of the tumor allowing for bet-
ter dosimetry through the course of therapy.
Some patients cannot be treated with the modi-
fied Stanford technique because of their inability to
stand safely or comfortably for extended periods.
An alternative technique exists where the patient
is treated in three supine and three prone positions
(lying-on-the-floor position). This technique has
shown comparable radiation quality and uniformity
with the modified Stanford technique.32
Dose
When RT is delivered to discrete lesions, larger
daily doses can be safely administered. In
contrast, treating the entire skin surface with
Fig. 4. The six treatment positions used for total skin electron beam therapy. (From Smith BD, Wilson LD. Man-
agement of mycosis fungoides. Part 2: treatment. Oncology 2003;17(10):1424; with permission.)
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fraction to prevent significant toxicity. This typi-
cally consists of 1 to 1.5 Gy each day. When lower
daily doses are used, higher total doses are neces-
sary to achieve comparable tumor responses.
Similar to local RT, a dose–response relation-
ship has been observed with TSEBT. Hoppe and
colleagues11 correlated the rate of CR with TSEBT
dose. He demonstrated a CR rate of 18%with less
than 10 Gy, 55% with 10 to 20 Gy, 66% with 20 to
25 Gy, 75% with 25 to 30 Gy, and 94% with doses
from 30 to 36 Gy. These data provide the rationale
for the recommendation that the total TSEBT dose
ranges from 30 to 36 Gy.14,17 At our institution, the
typical TSEBT prescription is 36 Gy at 1.5 Gy per
fraction using 6-MeV electrons. Treatment is deliv-
ered over 6 weeks. Daily doses of 1 Gy per fraction
are also commonly used with treatments delivered
over 9 weeks.
More recent experience has also shown
reasonable clinical outcomes with lower doses
of TSEBT. Harrison and colleagues33 reviewedthe Stanford experience with low-dose (<30 Gy)
TSEBT. Overall response rates (defined
as >50% improvement) were 90% in patients
receiving 5 to 10 Gy, 98% in patients receiving
10 to 20 Gy, and 97% in patients receiving 20 to
30 Gy. When compared with the standard dose
of greater than or equal to 30 Gy, CR rates were
reduced in the lower-dose groups. However,
PFS was comparable among the low-dose
groups and the standard dose. Furthermore, a
pooled analysis of three phase II clinical trials
including 33 patients treated with 12-Gy TSEBT
demonstrated an overall response rate of
88%.34 The median duration of response was
71 weeks. These data suggest low-dose TSEBT
may be a reasonable option for patients desiring
palliation of diffuse disease and who may not
tolerate the side effects and time commitment of
the standard course. Patients who receive the
low-dose TSEBT may also benefit from the ability
to repeat the regimen multiple times without
considerable toxicity.
Fig. 5. Patient undergoing total skin electron beam
therapy. Both internal eye and mouth shields are
used. The hands and feet are shielded and treated
separately with photon fields.
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TSEBT is given over a 6- to 10-week time period,
which can be logistically and emotionally chal-
lenging for patients. Furthermore, it is also associ-
ated with more acute toxicities compared with
local RT. However, most patients successfully
complete the planned course of therapy without
high-grade toxicity and long-term toxicities are
generally mild. Some patients might require a 10-
to 14-day break after 18 to 30 Gy to recover from
the acute toxicities of TSEB. Lloyd and col-
leagues35 described the type and grade of acute
treatment toxicities in 82 patients receiving TSEB
courses from 30 to 36 Gy. The most common tox-
icities included erythema/desquamation (76%),
blisters (52%), hyperpigmentation (50%), and
skin pain (48%). In their series, 32% of patients
had clinical evidence of a skin infection, which
was treated with antibiotics. There were no grade
4 or 5 acute toxicities.Close surveillance of patients by a multidisci-
plinary team is required to manage the acute
side effects of TSEBT. Patients receiving TSEBT
are seen formally by the radiation oncologist dur-
ing weekly treatment check visits. Symptomatic
treatments include moisturizers, topical and oral
analgesics, antibiotics when clinical infections
develop, and appropriate wound care. Close
collaboration with a wound care specialist is
important in promoting wound healing and pre-
venting infection.
Side effects that may develop following comple-
tion of TSEBT include alopecia (temporary vs per-
manent based on dose), dystrophic nails,
decreased ability to sweat, chronically dry skin,
cataracts, and telangiectasias. TSEBT has also
been associated with increased rates of second-
ary skin cancers.36–38PRIMARY CUTANEOUS ANAPLASTIC LARGE
CELL LYMPHOMA
Primary cutaneous CD301 lymphoproliferative
disorders are less common than MF and include
lymphomatoid papulosis (LyP) and primary cuta-
neous anaplastic large cell lymphoma (cALCL).
The Dutch Cutaneous Lymphoma Group pub-
lished a detailed report on a large series of patients
with CD301 lymphoproliferative disorders with
long-term follow-up.39 In addition, a more recent
consensus publication by the International Society
for Cutaneous Lymphoma, EORTC Cutaneous
Lymphoma Task Force, and the United States Cu-
tanous Lymphoma Consortium has addressed
treatment of these conditions.40 Based on their
observations and that of the National Comprehen-
sive Cancer Network, there are clinical guidelines
for diagnosis and treatment of the CD301 lympho-
proliferative disorders.
LyP is an indolent lymphoproliferative disorder.
Clinically this disorder is characterized by multi-
focal skin lesions that regress spontaneously
within 3 to 12 weeks. The prognosis of LyP is
excellent with a 5- and 10-year disease-related
survival of 100%.39 Of note, within the Dutch
cohort, 19% of patients with LyP had other asso-
ciated malignant lymphomas before, after, or
concurrent with LyP. There is no clear role for
RT for LyP.
In contrast to LyP, cALCL typically presents as a
solitary lesion or a localized group of lesions. The
prognosis of patients with localized disease is
excellent. Local RT is the first choice of treatment
in patients with a solitary or few localized nodules
or tumors (Fig. 6).39 A series from Stanford
demonstrated a CR in six of seven patients treated
with RT alone.41 Yu and colleagues42 reported on
Fig. 6. Localized primary cutaneous anaplastic large cell lymphoma at diagnosis (A) and 3 months after radiation
therapy (B).
Tandberg et al712eight patients with cALCL treated with 34- to 44-
Gy local RT. The CR was 100% and there was
no evidence of disease recurrence at a median
follow-up of 12 months. Finally, in the Dutch study,
99% of patients had a CR to initial therapy, 48% of
which were treated with local RT.39 Fifty-one
percent of patients developed recurrent disease
with the skin only being the most common site of
relapse (80% of patients with recurrent disease).
Relapses are almost always outside the previous
radiation field.REFERENCES
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